Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Immunicum AB announced that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in February.
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
The subscription price for warrant TO1 in Promore Pharma AB has been determined according to the terms and conditions forthe warrants to 23.30 SEK per share.
Immunicum AB has, as previously announced, implemented a share issue with preferential rights for the Company’s existing shareholders.
On January 3, Bristol-Myers Squibb announced it was buying Celgene for $74 billion. This would create a giant company with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease. As the companies release their fourth-quarter results, more details about the combined companies’ plans are emerging.
Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.
Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.